European Medicines Security Act

Infographic – Medicines Shortages: root causes and policies recommendations

It’s time to protect our medicines!

Infographic – Medicines Manufacturing

<strong><a class=”button small empty” href=”https://www.medicinesforeurope.com/wp-content/uploads/2023/05/Man-campaign-2022.png”>Open</a></strong>

One- Pager: New pricing models for generic medicines

How can we ensure a sustainable healthcare system while safeguarding continuous patient access to medicines?

Open

From disruption to care for cancer patients

Biosimilar medicines are biologic medicines that can be used safely and effectively in oncology and other therapy areas. Some of these medicines are so important that they are included in the WHO essential medicines list.

Open

Translating experience into regulation

More than 15 years of experience with biosimilar medicines show us that these medicines can be used to expand access to treatment, as they are just as safe and effective as their originator counterparts and can therefore be considered interchangeable with them.

Open

EU barometer for resilient access to biologics

Neurological diseases – Repurposing as an effective strategy to address unmet medical need

Integrated approaches – Investing in efficient IBD treatment, enabling innovation in patient care delivery